ASCO Annual Meeting

New Immunotherapy, MK-3475, Shows Promise for Metastatic Melanoma

ASCO Annual Meeting
June 2, 2014

According to the results of a large phase I study, a new drug called MK-3475 may benefit people with melanoma that has spread to other parts of the body. MK-3475 blocks the function of a protein called PD-1 (programmed death-1) found on T-cells, a type of white blood cell that directly helps fight disease. Because PD-1 keeps the immune system from destroying cancer cells, stopping PD-1 from working allows the immune system to better eliminate melanoma.

Chemotherapy Plus Either Bevacizumab or Cetuximab Are Equally Effective for Metastatic Colorectal Cancer

ASCO Annual Meeting
June 1, 2014

In a large, ongoing study, results indicate that two common treatment regimens approved by the U.S. Food and Drug Administration are equally effective for metastatic colorectal cancer. Metastatic colorectal cancer is cancer that has spread to other parts of the body.


Subscribe to RSS - ASCO Annual Meeting